+ T cells, may be considered for prevention or control of GVHD following allogeneic bone marrow transplantation, thus also explaining the increased resistance of mixed chimeras to GVHD.
Survival of lethally irradiated recipients after allogeneic blood or bone marrow transplantation (alloBMT) is mainly dependent on the number of hematopoietic stem cells present in the graft and the severity of the graft-versushost disease (GVHD) caused by immunocompetent donorderived T cells present in the graft. Complete prevention of GVHD can only be accomplished by eliminating mature alloreactive donor T cells in vivo or in vitro prior to transplantation. [1] [2] [3] [4] Unfortunately, effective depletion of bone marrow T cells may frequently result in an increased incidence of graft rejection and in recurrence of the primary malignancy due to loss of the graft-versus-leukemia (GVL) effect. [3] [4] [5] [6] On the other hand, immunosuppressive drugs such as cyclosporin A (CsA) given mandatory post transplantation, to recipients of T cell non-depleted marrow allografts can also decrease GVL and thereby cause relapse 7, 8 which may be reversed following discontinuation of CsA. 9, 10 Since the GVL effects induced by donor immunocompetent T cells are the main therapeutic indication for alloBMT, both T cell depletion or intensive post-transplant immunosuppression are detrimental to the treatment of hematologic malignancies. Ideally, GVHD should be prevented or at least better controlled by immunological means without any of the above measures, while taking advantage of the full benefits of GVL.
A direct correlation seems to exist between the intensity of the pre-transplant conditioning and the development of GVHD. Following intensive conditioning, GVHD tends to be severe and even more so after a second transplant.
11 Data in experimental animals indicate that mixed chimerism induced by milder conditioning and resulting in the presence of residual host-type hematopoietic cells, appears to be associated with a decreased incidence of GVHD, 12, 13 suggesting that residual host-derived immunohematopoietic cells may in fact contribute to GVHD resistance. We hypothesize that host hematopoietic cells can negate residual immunocompetent donor-derived T cells, and therefore may be used therapeutically to regulate donor anti-host alloreactivity.
In this study, mice with GVHD induced across major histocompatibilty complex barriers (MHC) were administered syngeneic, host-type lymphocytes in an attempt to balance the alloreactivity of donor T cells against the host, in order to simulate the resistance to GVHD observed in mixed chimeras. The results presented here indicate that veto effects by host-type cells should be further investigated as a new potential clinical tool to rescue patients with severe GVHD.
Materials and methods

Mice
) mice, 8-12 weeks old, were purchased from the Harlem Breeding Facility in Jerusalem, Israel. Mice were kept in a standard animal facility with top filtered cages. Cages, sawdust and water bottles were autoclaved once a week. Neomycin sulfate, at a concentration of 0.5%, was given in the drinking water for 2 weeks post transplantation.
Conditioning by radiation
F1 mice were exposed to 700 cGy total body radiation (TBI) delivered by a linear accelerator (Varian Clinac 6X) at a dose rate of 170 cGy/min, and a source to skin distance of 80 cm.
Spleen cell preparation
Spleen cells from donor mice were suspended in RPMI 1640 medium (Biological Industries, Bet Haemek, Israel), washed twice, resuspended in the same medium and injected into the lateral tail vein of recipient mice 24 h after conditioning.
Recombinant human interleukin 2 (rIL-2)
rIL-2 provided as 1 mg Proleukin equivalent to 18 × 10 6 international units, (IU) was kindly supplied by Chiron, Amsterdam, The Netherlands. rIL-2 was initially diluted with water for injection and subsequently re-diluted prior to injection with 5% dextrose.
Experimental design
F1 animals were chosen as recipients to exclude the possibility of rejection of donor cells causing GVHD by alloreactive host cells. One day following TBI, F1 mice were infused with 3 × 10 7 allogeneic (C57) spleen cells to induce GVHD. Animals were then divided into two groups: (1) mice injected with syngeneic F1 peripheral blood lymphocytes (PBL) (0. ml blood/mouse) or equivalent T cell subsets; (2) control mice received no further therapy. T cells and T cell subsets were depleted from spleen cells or blood by incubation with rat anti-mouse Thy1 antibodies (YTS 154), anti-CD4 (YTS 191) and anti-CD8 (YTS 169) antibodies at 2 mg/ml on ice for 15 min. Antibodies were prepared from hybridomas (provided by Dr S Cobbold, Cambridge University, UK) and injected immediately into the lateral tail veins of the mice. 
Monitoring of GVHD
Mice were observed daily for survival and clinical signs of GVHD, as manifested by diarrhea, weight loss and ruffled skin.
Results
Rescue of recipients from lethal GVHD across MHC by administration of host-derived whole blood or CD8
+ or CD4 + T cell subsets GVHD was induced by intravenous inoculation of 30 × 10 6 C57 spleen cells into F1 recipients conditioned on day 0 with TBI (700 cGy). Three days later, on day +4, mice were divided into four groups: (1) untreated control group; (2) recipients of host-type (F1) whole blood 0.5 ml/mouse i.v. (containing approximately 3 × 10 6 Thy1 + cells); (3) recipients of 0.5 ml host-type (F1) whole blood treated with anti-CD8 + antibodies; (4) recipients of 0.5 ml host-type (F1) whole blood treated with anti-CD4
+ antibodies. As shown in Table 1 , all 21 mice in the third group died within 45 days with typical signs of acute GVHD, as did 11 of 25 mice in the first group. In contrast, nine of 20 mice in the second group which received host-type whole blood, and all mice in the fourth group which received only CD4 + cell-depleted host-type blood remained alive and well with no evidence of GVHD for Ͼ60 days. The experiment was carried out twice with the same results.
Calculation of the percentage of donor cells in the blood or in the spleen of experimental mice by FACS analysis or by microcytotoxicity assay showed no difference between the different groups, indicating that the anti-GVHD effects were not due to loss of donor cells (Figure 1 ; Tables 2  and 3 ).
Rescue from lethal GVHD induced by mismatched (C57) spleen cells and rIL-2 in irradiated F1 recipients treated with host-type spleen cells
F1 mice were conditioned with TBI (700 cGy) and transplanted on day +1 with 30 × 10 6 allogeneic (C57) spleen cells. Low-dose rIL-2 (12 × 10 4 IU twice daily for 3 days) was given in parallel to facilitate induction of GVHD. Mice were then divided into 2 groups: (1) one group received syngeneic (F1) spleen cells; (2) the second group served as untreated controls (Figure 2 ). All control mice (n = 11) died within 9 days with typical signs of severe GVHD, whereas six of nine mice receiving F1 spleen cells, remained alive and well with no signs of GVHD for Ͼ110 days. At 4 months post transplantation chimerism was determined in the blood to confirm that elimination of GVHD was not due to graft rejection; 49-98% donor-type cells were detected in all the recipients tested (Table 2 and Figure 2 ). Our data indicate that administration of recipient blood after induction of GVHD, effectively down-regulated anti-host reactivity without altering the degree of chimerism in the recipient.
Discussion
Our experiments demonstrate that lethal GVHD may be successfully prevented by administration of host-type CD8 + blood lymphocytes. The anti-GVHD effects were not due to loss of donor T cells or reduction in the degree of chimerism since the percentage of donor cells present did not change as measured by both FACS and microcytotoxicity assays. Furthermore, T cell-mediated rejection of donorderived parental T cells of C57BL/6 origin by F1 recipients is not possible and rejection by NK cell-mediated hybrid resistance was ruled out by the constant degree of stable chimerism. Most likely, host T cells, especially CD8 + T cells, mediate their anti-GVHD effects by down-regulating anti-host reactivity through a veto mechanism which results in neutralizing anti-'self' responses. Therefore, administration of host-type blood to the chimeras may down-regulate GVHD by a mechanism similar to that in mixed chimeras, shown to be relatively resistant to GVHD induced by donor cells. 12, 13 Alternatively, anti-donor responses in C57 → F1 chimeras may be due to a veto mechanism induced by NK cells that mediate hybrid resistance 14 thereby avoiding the use of T cells. The latter explanation seems unlikely since the proportion of donor cells is expected to be reduced, or else elimination of CD8 + T cells would not result in abrogation of graft-versus-host alloreactivity. Nonetheless, the possibility that the anti-GVHD effects were mediated by CD8 + CD3 + NK cells acting as veto cells cannot be ruled out since 5-15% of NK cells can express CD8
+ . 15 Likewise, it cannot be ruled out that CD4
+ cells act as suppressor cells since anti-CD4-treated cells seemed to block GVHD better than untreated cells.
Control of GVHD by a veto mechanism induced by host hematopoietic cells is understandable if one considers the fact that mixed chimeras are consistently more resistant to GVHD in comparison with recipients reconstituted with 100% donor-type cells. The two most striking experiments in support of this observation are: (1) induction of bilateral transplantation tolerance of host-versus-graft and graft-versus-host in mice pretreated with total lymphoid irradiation (TLI); 12, 15, 16 and (2) mixed chimeras induced by Sharabi and Sachs, 13 Ildstad et al 17 and Sykes et al 18 in lethally irradiated recipients. Following conditioning with TLI with most of the host hematopoietic cells protected from irradiation in lead-shielded bones, stable mixed chimerism results as a rule in parallel with graft-versus-host tolerance, since chimeras show no clinical or pathological signs of GVHD. 12, 15, 16 Following conditioning of recipients with TBI, resistance to GVHD can also be documented after induction of mixed chimerism, further confirming our observations. Indeed, experiments in lethally myeloablated recipients reconstituted with a mixture of T cell-depleted host and T cell non-depleted donor bone marrow cells, resulted in GVHD-free chimeras whereas reconstitution of the same recipients with donor cells alone resulted in lethal GVHD. 13, 17, 18 Prevention or treatment of GVHD by infusion with host cells may be similar to induction of mixed chimerism since the coexistence of host hematopoietic cells with donor cells may be initially required for vetoing GVHD reactivity induced by donor-derived immunocompetent T cells. Veto capacity may thus be associated with non-immunogenic presentation of alloantigens by hematopoietic cells.
The concept of induction and maintenance of tolerance to alloantigens by the same veto mechanism may be supported by the state of mixed chimerism that seems to be crucial for induction of neonatal tolerance 19 and by the microchimerism established following liver transplantation and occasionally after transplantation of other perfused organ allografts. 20, 21 Interestingly, despite consistent induction of graft-versus-host unresponsiveness in the two experimental models involving TLI or TBI followed by infusion by a mixture of host and donor cells, both resulting in mixed chimeras, resistance to leukemia was retained in the recipients. 22, 23 Although tumor cells do express host MHC 24 against which tolerance was induced, mixed chimeras could still resist leukemic cells of host origin, suggesting that other cell surface determinants might be recognized by donor immunocompetent T cells. 22 We have previously shown that murine B cell leukemia (BCL1) can be eradicated within 2-3 weeks after transfer into bilaterally tolerant C57 → BALB/c chimeras without GVHD. 25 Therefore, one potential approach for eradicating resistant tumor cells regaining their cytokinetic potential post BMT could be by intentional induction of transient GVL/GVHD, as long as GVHD can be down-regulated or completely eliminated by donor T cells, in the case of severe GVHD. Our experiments suggest that it might be possible to down-regulate GVHD induced intentionally by infusion of host-type blood in which the main component, at least in C57 → F1 chimeras, seems to be CD8 + T cells.
Controlling alloreactive donor T cells by host blood cells, particularly CD8
+ T cells, suggests that the 'veto' effect may operate without physical elimination of donor T cells, thus perhaps enabling continuous induction of GVL despite control of GVHD. 25 In conclusion, if confirmed in additional experimental systems, this approach could form the basis for control of GVHD in man following allogeneic BMT across MiHC and MHC as well as following donor lymphocyte infusion for prevention or treatment of relapse post BMT. In some patients who received donor lymphocytes after transplantation and developed aplasia, infusion of host type cells can protect them from BM failure and susceptibility to infections.
